HIV treatment and prevention on every 2026 New Hampshire Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 9 stand-alone Part D plans in New Hampshire cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
| Drug | Wellcare Classic$0.00/moS4802-075 | Wellcare Value Script$0.00/moS4802-136 | HealthSpring Assurance Rx$0.00/moS5617-003 | Humana Basic Rx Plan$0.00/moS5884-101 | Humana Value Rx Plan$54.40/moS5884-181 | AARP Medicare Rx Saver from UHC$82.40/moS5921-378 | SilverScript Choice$94.90/moS5601-002 | AARP Medicare Rx Preferred from UHC$104.30/moS5921-384 | Humana Premier Rx Plan$150.20/moS5884-148 |
|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 427% | Tier 440% | Tier 430%QL 300/30d | Tier 433%QL 180/30d | Tier 431%QL 180/30d | Tier 436%QL 180/30d | Tier 433% | Tier 430%QL 180/30d | Tier 450%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525% | Tier 525% | Tier 525% | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 531%QL 30/30d | Tier 533%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 427%QL 30/30d | Tier 440%QL 30/30d | Tier 430%QL 30/30d | Tier 433%QL 30/30d | Tier 431%QL 30/30d | Tier 436%QL 30/30d | Tier 433%QL 30/30d | Tier 430%QL 30/30d | Tier 450%QL 30/30d |
| Tivicaydolutegravir | Tier 525% | Tier 525% | Tier 430%QL 180/30d | Tier 525%QL 60/30d | Tier 526%QL 60/30d | Tier 525%QL 60/30d | Tier 525% | Tier 531%QL 60/30d | Tier 533%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.